Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
How would one approach adjuvant therapy in mid ureteral urothelial carcinoma s/p nephroureterectomy and residual borderline renal function?
Related Questions
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
How would you treat a patient with ESRD on hemodialysis with good risk metastatic seminoma with bulky retroperitoneal adenopathy?
How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?
Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
What is the minimum duration to be on bicalutamide prior to starting GnRH agonist in de novo metastatic prostate cancer with significant bone disease?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
